Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation

Biol Blood Marrow Transplant. 2015 Jul;21(7):1155-66. doi: 10.1016/j.bbmt.2015.03.002. Epub 2015 Mar 11.

Abstract

Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered in the context of this evolution. In this evidence-based review, we have critically analyzed the data from the most recent clinical trials to better understand how to incorporate HCT and when HCT is indicated. We have provided our recommendations based on strength of evidence with the knowledge that ongoing clinical trials make this a dynamic field. Within this document, we discuss the decision to proceed with autologous HCT, factors to consider before proceeding to HCT, the role of tandem autologous HCT, post-HCT maintenance therapy, and the role of allogeneic HCT for patients with MM.

Keywords: Guidelines; Multiple myeloma; Recommendations; Transplantation.

Publication types

  • Guideline
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Age Factors
  • Chromosome Aberrations
  • Disease Management
  • Evidence-Based Medicine
  • Gamma Rays / therapeutic use*
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Multiple Myeloma / genetics
  • Multiple Myeloma / pathology
  • Multiple Myeloma / therapy*
  • Myeloablative Agonists / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Time Factors
  • Transplantation Conditioning / methods*
  • Transplantation, Autologous
  • Transplantation, Homologous

Substances

  • Myeloablative Agonists